Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Chimerix Appoints CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Chimerix Appoints CEO

Berrey succeeds Moch

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

M. Michelle Berrey, M.D., M.P.H. has been appointed president and chief executive officer of Chimerix, Inc. Dr. Berrey will continue to serve as chief medical officer. Dr. Berrey succeeds Kenneth I. Moch, who has resigned to pursue other interests.
 
Prior to joining the company, Dr. Berrey served as chief medical officer at Pharmasset, Inc. since 2007, a company focused on the development of nucleotide analogs for the treatment of hepatitis C, until its acquisition by Gilead Sciences, Inc. in January 2012.
 
“We are grateful for Ken’s contributions to Chimerix and his leadership during the company’s transition to a publicly traded company. We are now entering a critical stage of the clinical development of brincidofovir. Our goal is to complete the requirements for regulatory approval of brincidofovir as rapidly as possible and we believe Dr. Berrey has the qualifications and expertise in abundance to accomplish that objective,” said Ernest Mario, Ph.D., chairman of the board of directors. “I believe Dr. Berrey has demonstrated the leadership skills and vision to guide Chimerix through this critical phase in the company’s evolution.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters